Compare SPRO & INVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPRO | INVE |
|---|---|---|
| Founded | 2013 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer peripheral equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.5M | 115.7M |
| IPO Year | 2017 | 1997 |
| Metric | SPRO | INVE |
|---|---|---|
| Price | $2.79 | $4.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | ★ 663.0K | 171.3K |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 111.81 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $66,802,000.00 | $60,219,000.00 |
| Revenue This Year | N/A | $22.10 |
| Revenue Next Year | $300.00 | $20.74 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 39.24 | 7.21 |
| 52 Week Low | $1.80 | $3.08 |
| 52 Week High | $3.09 | $5.30 |
| Indicator | SPRO | INVE |
|---|---|---|
| Relative Strength Index (RSI) | 55.64 | 46.44 |
| Support Level | $2.18 | $3.24 |
| Resistance Level | $2.90 | $4.07 |
| Average True Range (ATR) | 0.17 | 0.25 |
| MACD | 0.03 | -0.07 |
| Stochastic Oscillator | 58.45 | 26.24 |
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Identiv Inc develops specialty radio-frequency identification (RFID) and Internet of Things It (IoT) solutions that address customers' challenges and create new opportunities for them through the digitization and enhanced connectivity to the IoT. It designs, produces, and sells RFID and Bluetooth Low Energy (BLE) enabled devices, RFID inlays, tags, and labels that can be applied or incorporated into physical objects, providing them with a digital identity and the ability for customers to track, monitor, authenticate, and engage with consumers. Its IoT Business segment develops, manufactures, and supplies specialty IoT solutions tailored for the healthcare, logistics, smart packaging industries and other high-value end markets.